Skip to content

Comparison of the efficacy of pulsed thulium laser versus holmium laser in transurethral anatomical prostate enucleation - a prospective randomized controlled trial

Comparison of the efficacy of pulsed thulium laser versus holmium laser in transurethral anatomical prostate enucleation - a prospective randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094861
Enrollment
Unknown
Registered
2024-12-30
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

Pulsed thulium laser group:Transurethral anatomical prostate enucleation using pulsed thulium laser.
Holmium laser group:Transurethral anatomical prostate enucleation using holmium laser.

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Male, regardless of age, patients with indications for surgery according to the 2019 Chinese Guidelines for the Diagnosis and Treatment of Urological Diseases: 1. Patients with BPH with moderate-severe LUTS that have significantly affected quality of life, especially those who do not respond well to medication or refuse to receive medication. 2. When BPH is combined with the following complications: recurrent urinary retention; recurrent hematuria; recurrent urinary tract infections; bladder stones; Secondary upper urinary tract hydrops (with or without renal impairment). 3. Patients with BPH combined with inguinal hernia, severe hemorrhoids or prolapsed anus, and it is difficult to achieve the treatment effect without relieving the lower urinary tract obstruction. 4. Signed informed consent form and willing to participate in the investigator.

Exclusion criteria

Exclusion criteria: 1. Patients with urethral stricture. 2. Neurogenic bladder. 3. Forcing muscle weakness. 4. History of previous prostate surgery or lower urinary tract surgery. 5. Patients with comorbidities of other serious systemic diseases. 6. Patients with coagulation disorders or undergoing anticoagulation therapy.

Design outcomes

Primary

MeasureTime frame
Operative time;Intraoperative bleeding volume;

Countries

China

Contacts

Public ContactChun Jiang

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

jiangch@mail.sysu.edu.cn+86 135 8057 4886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026